Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB).
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi (SNY)
TD Cowen analyst Steve Scala maintained a Hold rating on Sanofi today and set a price target of $57.00. The company’s shares closed last Tuesday at $47.71.
According to TipRanks.com, Scala is a 5-star analyst with an average return of
Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $59.50.
See today’s best-performing stocks on TipRanks >>
Milestone Pharmaceuticals (MIST)
H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Milestone Pharmaceuticals today and set a price target of $8.00. The company’s shares closed last Tuesday at $1.13.
According to TipRanks.com, Folkes is a 1-star analyst with an average return of
Currently, the analyst consensus on Milestone Pharmaceuticals is a Moderate Buy with an average price target of $8.00, representing a 676.7% upside. In a report issued on March 23, TD Cowen also maintained a Buy rating on the stock with a $8.00 price target.
Connect Biopharma Holdings (CNTB)
Northland Securities analyst Carl Byrnes maintained a Buy rating on Connect Biopharma Holdings today and set a price target of $7.50. The company’s shares closed last Tuesday at $2.92.
According to TipRanks.com, Byrnes has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Connect Biopharma Holdings with a $8.38 average price target, a 201.4% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $10.00 price target.
Read More on SNY:
Disclaimer & DisclosureReport an Issue
- Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says
- HLTH, ESIH, HLT: Look to Europe for Healthcare ETFs
- Sanofi Wins FDA Breakthrough Therapy Status for Venglustat in Type 3 Gaucher Disease
- Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan
- Sanofi Advances Early Autoimmune Antibody Program With New Phase 1 Study Update
